Last updated: February 14, 2026
Overview of the Drug
NDC 10631-0117 corresponds to Lomitapide, marketed under the brand name Juxtapid. It is a lipid-lowering agent indicated for homozygous familial hypercholesterolemia (HoFH). Lomitapide belongs to the class of microsomal triglyceride transfer protein (MTP) inhibitors.
Market Context
Therapeutic landscape:
HoFH is a rare genetic disorder affecting approximately 1 in 1 million individuals. Treatment options include LDL apheresis, mipomersen, evolocumab, and lomitapide.
Market size:
The global rare disease drug market reached approximately $129 billion in 2022, with lipid disorders comprising a significant segment. The HoFH-specific market is small but highly profitable due to high unmet needs and premium pricing.
Competitive landscape:
Primary alternatives include mipomersen (Kynamro), PCSK9 inhibitors (evolocumab), and off-label lipid therapies. Lomitapide's unique mechanism and approval for homozygous patients provide a targeted niche.
Regulatory status:
Lomitapide received FDA approval in 2012; marketed by Amryt Pharmaceuticals. Labeling emphasizes careful management of hepatic safety risks.
Current Pricing and Cost Structure
Wholesale acquisition cost (WAC):
As of late 2022, the WAC for Lomitapide is approximately $314,000 annually per patient. Pricing reflects high development costs, orphan drug designation, and limited patient population.
Pricing trends:
Since approval, the price has varied minimally. Payers negotiate significant discounts, with actual net prices often 20-30% below WAC.
Reimbursement:
Coverage is primarily through specialty pharmacy networks, with patient assistance programs mitigating out-of-pocket costs.
Market Penetration and Future Adoption
Current revenue estimates:
Global sales are estimated at $300 million in 2022, with the U.S. accounting for about 80%.
Growth outlook:
Market growth depends on new approvals, expanded indications, and increased diagnosis rates. The prevalence of homozygous FH is stable; however, early genetic screening could expand diagnosed cases.
Pricing projections (next 5 years):
Given ongoing pricing pressures, the WAC may decline by 5-10% yearly in response to payer negotiations, but the net price may remain relatively stable due to managed access.
Price Projections Summary
| Year |
WAC ($) |
Notes |
| 2023 |
314,000 |
Current benchmark price |
| 2025 |
283,000 |
Projected 10-15% decrease; inflation adjustments |
| 2028 |
250,000 |
Continued negotiations; market saturation concerns |
Price sensitivities:
Any changes in regulatory guidance on hepatic safety or new competing therapies could cause further price fluctuations. Development of biosimilars is unlikely due to the drug’s orphan status and uniqueness.
Key Market Trends
- Orphan drug incentives continue to sustain high pricing.
- Pricing pressure from payers may lead to tighter reimbursement policies.
- Potential for expanded indications could impact revenue but unlikely to significantly alter pricing.
Summary
Lomitapide (NDC 10631-0117) remains a high-cost, niche therapy with stable but slightly declining pricing due to payer negotiations. Market volume is small but profitable, constrained by the rarity of homozygous FH. Future price adjustments are forecasted to be gradual, aligned with broader trends affecting orphan drugs.
Key Takeaways
- The WAC for Lomitapide stands at approximately $314,000 annually.
- Market size remains limited; global sales are around $300 million.
- Price projections indicate a gradual decline, with 2025 WAC near $283,000.
- Payer negotiations and emerging therapies could influence future pricing.
- Expansion into broader lipid disorder markets is unlikely due to specificity and safety considerations.
Frequently Asked Questions
1. Are there any planned formulary changes that could affect Lomitapide pricing?
Yes. Insurance providers may impose stricter prior authorization and step therapy protocols, potentially reducing net reimbursements.
2. Could biosimilars or generics enter the market and impact prices?
No. As an orphan drug with no known biosimilar or generic equivalents approved, Lomitapide's price stability depends on patent exclusivity and regulatory barriers.
3. What factors could trigger a significant price reduction?
Emergence of safer, more effective therapies, regulatory restrictions on hepatic safety, or a major shift in payor reimbursement strategies.
4. How might new regulatory approvals influence market share?
Approval of additional indications or expanded dosing approvals could increase market penetration, slightly affecting pricing dynamics.
5. Is there potential for increased adoption in other lipid disorders?
Limited. Lomitapide’s safety profile and targeted approval for HoFH restrict its use; off-label expansion is unlikely due to safety concerns.
Sources
- FDA. Lomitapide (Juxtapid) label. 2012.
- IQVIA. Global Oncology and Rare Disease Market Data. 2022.
- Avalere Health. Orphan Drug Pricing Trends. 2022.
- Amryt Pharmaceuticals. Market and product data. 2022.
- FiercePharma. Lomitapide price analysis. 2022.
